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Abstract 
A current advance within the agricultural industry is the use of genetic engineering to produce 
novel crops for food production. This technology raises questions about how societies should 
position themselves with respect to genetically modified (GM) crop development and 
implementation; namely, how should the potentials and risks of this technology be evaluated? 
We argue that current methods to evaluate the risks and benefits of GM crops are inadequate and 
not conducive to the strategic development of this technology, where a way to ameliorate 
technology assessments for GM crops is to include farmers in the research process of evaluating 
these crops prior to their commercialization. However, particularities concerning the ethical 
status of such research require special consideration and vigilance. For example, in such 
technology assessment initiatives, farmers would occupy both the roles of research participant 
and research investigator. Other particularities surface due to factors related to the nature of GM 
crops. These particularities are examined with reference to concepts drawn from the field of 
research ethics, namely informed consent, compensatory decisions, and issues of participant 
inclusion/exclusion. 
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I. INTRODUCTION 
 The global agriculture sector has undergone numerous transformations over the past 
century. Innumerable advances have been made in the development of synthetic fertilizers, 
pesticides and herbicides, and technologically advanced machinery has significantly reduced 
labour-intensive cultivation practices in developed countries. Traditional forms of agriculture 
such as subsistence farming are now largely overshadowed by a global trend towards 
industrialization.(1, p. 375) Even the major plants cultivated today have been carefully bred with the 
goal of enhancing traits that best suit industrial agricultural production, resulting in crops that 
bear little resemblance to their initial ‘wild’ progenitors. The Green Revolution of the late 1960s 
resulted in significant increases in agricultural yield and efficiency for many(1, p.363-365) but not all 
regions of the globe. Many of the poorest nations remain unable to implement novel agricultural 
innovations due to, amongst other factors, significant resource constraints; many farmers can 
simply not bear the costs associated with “high tech” agriculture.(2) 
 
A period of intense research and development, the 1960s produced a diversity of new 
high-yield varieties of staple crops (e.g., wheat, corn, rice) and introduced many advanced 
farming practices (e.g., the use of fertilizers, pesticides, irrigation). These innovations enabled 
many farmers (and nations) to feed the world’s burgeoning population; the fact that famine 
remains endemic in many countries is attributable to a range of complex social, political, and 
economic factors (e.g., issues of international trade, agricultural subsidies and protectionism) that 
go beyond simple production capacity. As with so many technological innovations, the benefits 
derived from Green Revolution technologies were also accompanied by significant negative 
consequences for certain interests or stakeholders. Agriculture has become increasingly the 
domain of major farm corporations, to the exclusion of small family or subsistence farmers; and 
the associated exorbitant use of chemical fertilizers and pesticides necessary for massive 
monoculture practices have contributed to environmental degradation.(2) 
 
Today, the international agriculture sector is experiencing significant pressures, in part 
from a growing global population and the near maximal use of arable land for food production, 
but also from the increasing competition made possible by globalisation. These issues have 
raised questions for many policy makers in developed nations about whether existing methods to 
improve crop varieties and farming practices are sufficient.(3, 4) Vasil, for example, has argued 
that “most of our major crops have reached the physiological limits of productivity…[i]t is no 
longer possible to significantly increase the yield in these crops by conventional breeding 
methods”.(4) Further, many widely used herbicides and pesticides that have greatly contributed to 
large yields in agricultural production are becoming ineffective in controlling pests and weeds; 
for example, more than 500 species of insects have developed tolerance to a wide range of 
common pesticides.(5) In the context of industrial agriculture, there is arguably a pressing need 
for the development of technologies and strategies that can ensure food production stays in-step 
with global population growth (a discussion of the social, economic or political aspects of 
equitable global food distribution and access is beyond the scope of this paper). 
 
One response to this challenge has been the development and application of genetically 
modified (GM) crops into industrial agricultural practices.(4, 6-8)* Genetic engineering technology 
                                                
* Also described as a genetically modified organisms, these modifications include the removal, alteration, and 
addition of genes so that the newly engineered organism acquires novel attributes. 
 3 
entered the agricultural sector in the early 1990s, marking the beginning of an era that some have 
termed the ‘Gene Revolution’.(6) The first generation of GM crop varieties typically had added 
insect resistance or herbicide tolerance,(6) attributes that in many contexts have significantly 
increased crop yield, production efficiency, farmer income, and efficacy of insect/weed 
management.(9-12) These observed benefits motivated many farming communities (and nations) 
to embrace the technology. The cultivation of GM crops has shown near linear growth in both 
the developed and developing world, and they are now grown in over 20 countries.(6, 13, 14) 
Second generation GM crops include traits such as drought tolerance, as well as the ability to 
produce pharmaceuticals, vaccines, and nutrient enriched varieties of otherwise nutrient-poor 
staple crops.(6, 8, 15)  
 
The introduction of genetic engineering into the agricultural sector has resulted in more 
than novel plant varieties; it has also led to significant public and policy debate around the world. 
The current academic and policy literatures on GM crops are still full of disagreements about the 
usefulness and risk to the environment and public health of these technologies.(7, 16) Not 
surprisingly, then, debate about the utility GM crops is highly politicized, even polarized.(17, 18) 
Numerous surveys also repeatedly demonstrate public resentment in many developed countries 
(particularly in Europe) towards the consumption of GM food products;(6, 19-21) the genetic 
modification of living organisms is for many people fundamentally ‘unnatural’ and thus 
unethical.(22) At the same time, consumers – particularly in North America – demand access to a 
diversity of low cost food products, regardless of the production or growing season. In this 
context, it is not surprising that farming in the developed and (increasingly) the developing world 
has become, and arguably will remain, a high tech science; and the genetic manipulation of crops 
is the latest tool in the arsenal of farming practices aimed at meeting the food requirements of a 
growing world population. However, as is case with the technological developments of the 
Green Revolution, it is important to note that emerging genetic engineering technology alone 
will unlikely result in a complete solution to the complex issue of global hunger. GM crops may 
be necessary, but they are not sufficient; social, political and economic transformations of 
national and global agriculture policies and practices are also required. 
 
The novelty and uncertainties associated with GM technology clearly raise important 
questions about how developed countries are to position themselves with respect to the safe 
implementation of GM crops and production of GM derived food products. If the aim is to 
encourage agricultural advances that best serve the needs of society, how can this be done in a 
fashion that is both strategic (economically and politically) and publicly accountable? More to 
the point, how should regulators and policy makers assess this technology in order to identify 
and maximize its social and economic benefits, while minimizing the risks to human and 
environmental health, and more generally, mitigating the possibilities for social injustice and 
other risks to society? 
 
This article aims to address these questions by arguing that current methods used to 
assess GM crops are inadequate. In developed countries, regulatory standards for the 
commercialization of GM crops focus too much on risk assessment; benefit assessments, if they 
are done at all, are too passive since they are invariably performed after product 
commercialization. Furthermore, such assessment procedures are exclusively technocratic in 
nature and do not assess broader social, political and cultural dimensions of agriculture. Current 
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assessment processes are thus inadequate for the strategic development of GM crops. A solution 
to the above weaknesses, it will be argued, resides in the greater inclusion of farmers (a key 
stakeholder group) into research and assessment procedures of agricultural innovations. Indeed, 
there is a growing recognition – or at least a public discourse – among many policy makers and 
academics about the importance and utility of including various stakeholder groups in policy 
development; the idea is that if diverse public voices or perspectives are “at the table”, then this 
will lead to better (i.e., more representative, equitable, and publicly acceptable) policy.(23, 24) 
Overall, we argue that the strategic development of GM crops entails moving beyond the 
traditional reliance on techno-scientific analyses of risk and benefit, to a more fully integrated 
reflection on the range of farmer interests and values at stake in contemporary agriculture.(25) 
 
However, if farmers are empowered and integrated in the assessment and development of 
GM crops, what principles should be followed to ensure that this process is ethical? Instead of 
drawing on the tools of deliberative democracy (e.g., public consultation, questions of 
representation) that have been used widely in this and other related contexts, we will refer to the 
academic literature and international standards in research ethics, specifically that which regards 
the involvement of human subjects in investigative research. We argue that attention to issues of 
informed consent, compensatory decisions, and the equitable inclusion or exclusion of 
participants can help clarify and better structure the ethical responsibilities of the various 
stakeholders involved in the assessment and strategic development of new agricultural 
technologies.   
 
II. DISCUSSION 
A. Current Assessment Processes for GM crops: Risks and Benefits 
 Unlike novel plant varieties produced via more traditional methods (such as by cross 
breeding and the formation of hybrid species), international regulatory standards require that GM 
crops undergo a series of field trial assessments prior to their commercialization.(26, 27) This 
specific regulatory oversight of GM crops exists because certain GM cultivating nations have 
acknowledged that plant varieties produced by genetic engineering carry a greater potential risk 
to the environment and public health. Canada is an exception, where equivalent regulatory 
standards are applied to any new plant variety, regardless of whether it is developed through 
genetic engineering or other traditional plant breeding methods.(26) 
 
 Field trial experiments for GM crops typically proceed through three stepwise phases.(26, 
27) At each phase, the crop is assessed for potential environmental risk factors. Typical factors 
assessed include the potential for the GM crop to become a weed (i.e., a problematic plant 
species); the ability of the crop to transfer the genetic modification to other organisms; the 
stability/inheritability of the genetic modification; potential pathogenicity to other organisms; 
and whether the GM crop has the potential to produce environmental toxins. The initial field trial 
phase involves cultivating the crop in an enclosed greenhouse, isolated from the exterior 
environment. In the second phase, the GM crop is cultivated in open fields that are (in principle) 
isolated from other farm plots. Products from these field trials are subsequently disposed of and 
do not reach the market for human or animal consumption.† The last phase involves cultivating 
the GM crop in large unconfined fields. Once successfully through the environmental risk 
                                                
† A notable exception was the inadvertent and highly publicised detection of Starlink Bt corn in Taco Bell taco 
shells; this GM corn had only been approved for use in animal feed. 
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assessment, the crop is labelled as being low risk to the environment and thus can be 
commercialized for agriculture production. Regulatory oversight continues post-
commercialization in order to identify whether environmental problems arise from the broad 
cultivation of the GM crop. Aside from field trial environmental impact studies, GM crops also 
undergo assessments that focus on identifying risks to human health.(26, 27) These assessments 
typically focus on whether the genetic manipulation of the crop produces unpredictable 
alterations in biochemical composition, alters its nutritional quality, or introduces novel toxins or 
allergens. Government regulatory oversight of GM crops is thus technocratic and primarily 
aimed at assessing whether novel plant varieties possess significant risks to human health or to 
the environment.  
 
But what about factors that fall outside the classification of risks? How are the benefits of 
GM crops assessed? Currently, it is mainly academic researchers who perform benefit 
assessments of these crops. As previously mentioned, the first generation and most widely 
cultivated GM crops have the added genetic traits of herbicide tolerance or insect resistance, 
traits that can simplify weed and pest management strategies by reducing the need for large scale 
application of chemical pesticides or herbicides.(28, 29) Post-commercialization research has 
focussed on the impact on pesticide and herbicide usage, studies which essentially confirm 
whether these crops indeed produce the benefits which they were designed to provide.(9-11, 28, 30, 
31)   
 
Many studies have also addressed the question of whether the cultivation of GM crops 
possess economic advantages in comparison to the cultivation of non-GM varieties. That is, they 
examine the ‘obvious’ economic benefit to farmers – why would farmers embrace this 
technology if it could not provide significant economic gains?(13) Indeed, some economic 
analyses have demonstrated that cultivation of GM crops can increase production yields and 
decrease the use of chemical pesticides and herbicides.(9-11, 30, 31) Interestingly, these studies, 
which focussed on affirming obvious benefits, have also identified additional benefits that were 
not inherently predictable with herbicide tolerant and insect resistant GM crops. Many of these 
benefits are social, health, and environment related, some of which will be described briefly. 
 
In the context of social factors, better pest and weed management from GM crops can 
reduce farmer stress and allow for more efficient work habits.(31) The ability for farmers to better 
control pest infestations with insect resistant varieties can minimize the risks of crop loss due to 
unpredictable fluctuations in insect infestations. This reduced risk has meant that some farmers 
are less concerned about the success of their harvests; in other words, the farmer can gain a 
“greater peace of mind”.(10) This is particularly significant in certain regions of the world where 
stress originating from insect infestations is a leading cause of farmer suicide.(10) In relation to 
herbicide tolerant crops, the ability to apply only one herbicide to control weeds has translated 
into decreased workload and time savings. This provides farmers with more time, flexibility, and 
resources to focus on the cultivation of other crops.(31) 
With regards to health factors, the adoption of insect resistant GM crops in certain 
regions of the world has reduced the incidence of farmer poisoning due to the heavy use of toxic 
farm chemicals.(9) For example, many cotton farmers in China apply pesticides manually and 
without protective clothing; the introduction of insect resistant GM cotton has sharply reduced 
chemical pesticide applications, and thus, toxic exposures to these compounds. In the context of 
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environmental factors, the decreased need to apply herbicides and pesticides with GM crops can 
reduce the use of machinery that applies these chemicals. Aside from the environmental gains of 
using fewer chemicals, the decreased use of farm machinery can lower gasoline consumption and 
thus decrease air pollution and green house gas emissions.(10, 28) 
To summarise, assessments performed on GM crops after their commercialization 
typically demonstrate their obvious utility in farming practice, such as reductions in pesticide and 
herbicide use and the potential for economic advantages. However, these assessments also 
uncover unexpected potential benefits that were not inherent in the initial proposition or 
justification for this technology. That is, there are non-obvious social, health, and environmental 
benefits that can arise with the use of GM crops. It is important to bear in mind, however, that 
farmers around the world do not share these benefits uniformly or consistently. 
   
B. Inclusion of farmers in the assessment of GM-crops 
 The current technocratic approach to technology assessment of GM crops – with its focus 
on identifying risks and only post-commercialization examination of potential benefits – raises 
important questions. First, do current methodologies promote strategic technology development? 
And do they adequately address the needs of farming communities and empower farmers in the 
development of their industry?  
 
 It is our contention that current assessment procedures for GM crops are not conducive to 
strategic technology development. In order for policy makers to make decisions on how to 
strategically subsidize and encourage the broad distribution of promising technologies, they must 
be provided with detailed information concerning utility, benefits and risks prior to the 
technology’s commercialization.(32) Regulatory risk assessments fail in this regard for they focus 
exclusively on risks, while the identification of obvious (i.e., economic) benefits are passively 
assessed after the commercialization of crop varieties. Furthermore, certain weaknesses are 
observable only after the GM crop has been cultivated within a ‘real-world’ setting. Such an 
approach is generally not conducive to sustainable development efforts, and is likely short 
sighted with respect to ethical and social concerns. A better strategy for technology assessment 
and eventual adoption is to base decisions on more well rounded perceptions of potential social 
benefit that include social and ethical considerations.(32) Yet in relation to GM crops, which 
societal group is best suited to address and define the benefits, risks, and the socio-ethical 
concerns associated with this technology? Obviously, consumers and environmental interest 
groups are important stakeholders, and they have been key vocal participants in discussions 
about and analyses of GM crops. But another key and often neglected group is the people who 
will actually implement the technology in question, namely farmers.  
 
 So far, our discussion of GM crops has focused largely on the potential benefits for 
farmers; but as with other agricultural developments (e.g., monoculture, automation), the use of 
GM crops also has the potential to harm certain farming communities. To begin with, the 
introduction of novel technologies in global agricultural systems is often associated with 
injustices and the absence of sustainable development.(33) Despite consistent improvements in the 
efficiency and productivity of agriculture, new capabilities do not benefit the poorest nations nor 
the small-scale farmer. Technological advances seem invariably to be best suited to large 
industrial farms in developed and developing countries, and GM crops are no exception. For 
example, Hall and colleagues(34) demonstrate that the introduction of herbicide tolerant crops into 
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Brazilian agriculture has almost exclusively been of economic benefit to industrial farms. These 
crop varieties have remained out of reach of small-scale subsistence farmers due to their poor 
resource capacities (e.g., inability to pay high seed costs) and marginalized status. The ability of 
industrial farmers to acquire GM crop technologies has had the effect of furthering the social 
exclusion and economic depravation of small subsistence farmers in Brazil.(34)  
 
Another risk to certain farm communities stemming from the cultivation of GM crops 
relates to unforeseen complexities in the management of weeds and insects. Exclusive reliance 
on and excessive use of a given pesticide raises the possibility for the development of pest-
resistant weeds and insects. In relation to GM crop farming, the exclusive use of the herbicide 
glyphosate for weed management in the cultivation glyphosate-tolerant GM-crops has resulted in 
the evolution of glyphosate-tolerant weeds in the United States.(35) This in turn has inhibited 
farmers’ abilities to effectively manage weed infestations with resultant economic losses. 
 
A final example of unexpected GM crop risks that have harmed specific farm 
communities pertains to over-estimated yield gains expected from a given genetic modification. 
The cultivation of Bt-cotton in India is exemplary.(36) The introduction of insect-resistant Bt-
cotton was encouraged by Indian policy makers due to promised increases in yield from 
reductions in pest-related losses. However, mass cultivation within a ‘real-world’ setting has 
resulted in minimal yield gains since multiple environmental factors have apparently neutralized 
any gains expected from better pest management. Overall, the broad cultivation of Bt-cotton has 
demonstrated “the fact that yields are much more complex in reality than a linear function of one 
technology”.(36) In turn, mass cultivation of Bt-cotton within certain Indian farming communities 
has put ‘all their eggs in one basket’, and thus diverted limited resources away from more 
economically stable practices such as diversifying agricultural production capacities.  
 
What actions could be taken to reverse or mitigate such social inequities in the 
agricultural sector, and how can real-world problems such as herbicide resistance and 
discrepancies in expected yield gains be more readily identified? For a start, policy makers might 
preferentially support and promote the commercialization of innovations that are likely to be of 
equal benefit to all members of the farming community, and not just for large-scale industrial 
farms. This would entail consideration of how a particular innovation would be taken up by 
different types of farmers (small and/or subsistence vs. large scale), the economic costs of 
purchasing the innovation (is it affordable for all farmers?), and how it could be best integrated 
(or not) into existing farming practices. With this knowledge, policy makers might then consider 
implementing appropriate social safety mechanisms to counter any likely injustices (e.g., by 
providing subsidies to some farmers to purchase the innovation).  
 
But how are policy makers to evaluate whether a given technology can benefit farmers 
equally? And conversely, how can the potential for harm be assessed for all population segments 
of an increasingly globalised agricultural industry? One possible solution is to empower farmers 
and integrate them in the process of developing and assessing emerging agriculture technologies. 
This system would improve on current assessment methodology by moving beyond government 
and corporate-sponsored research that focuses on assessing the obvious benefits and potential 
risks of the GM crop to the exclusion of broader social and cultural farming practices that are 
equally important in evaluating the merits and legitimacy of emerging agricultural technologies. 
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Overall, in order for the development of agricultural innovations to be strategic and publicly 
acceptable, technology assessments must move beyond a narrow technocratic process. That is, 
policy makers should – whether through their own analyses, or through more direct farmer-
centred consultations – pay particular attention to the social, economic and moral values at stake 
related to the future commercialization and broad implementation of GM crop varieties.  
 
C. Ethical Principles and Challenges with Farmer Participation in GM Crop Research    
 Including farmers as key stakeholders in pre-commercialization technology assessments 
– similar to what has been suggested for improving health technology assessment(37, 38)– may be 
an effective means to identify the obvious benefits of an innovation, as well as the non-obvious 
benefits and potential risks that farmers should expect from the introduction of novel GM-crop 
varieties. Nonetheless, it is important to also consider ethical principles and specific challenges 
associated with such a process. Specifically, for our purposes the issues of primary interest are 
those concerning informed consent, compensation, and the inclusion of various farmer 
populations in research initiatives. As we will demonstrate, assessing these ethical issues is 
important for several reasons. At the most general level, attention to these ethical principles – 
and the challenges facing farmers – highlights the fact that farmers are, and should be treated as, 
active participants in the research and technology development process. To not attend to these 
principles is to reinforce a view of farmers as passive recipients of technology, unable to 
question the utility or appropriateness of a particular innovation. Such a paternalistic view has 
largely been rejected in the health field – patients and research ‘subjects’ are now increasingly 
recognised as active collaborators in healthcare choices and ‘participants’ in the research 
process. By analogy, in the agricultural context, the concept of empowering farmers – something 
that is widespread both in agricultural policy and commercial messages – is meaningless if one 
does not also attend to principles of autonomy, informed consent, and participation in the 
research process.  
 
In practice, farmers can and often do participate in corporate-sponsored agricultural 
research, where their autonomous consent to conduct assessments is certified through a contract 
agreement. However, such methodology does not taken into account the major power imbalance 
between agrobiotech or seed companies and farmers; the potential for active participation based 
on a “fully informed consent” will be significantly limited, when compared to non-industry 
funded or more open agricultural (e.g., academic) research. As is the case in the conduct of 
clinical trials for development of novel medicines, there is a world of difference between 
pharmaceutical industry-sponsored research where the company sets the agenda and the “rules of 
the game”, and academic/university research where researchers are able to define and re-define a 
line of inquiry, and even include patients as active participants or collaborators. These 
differences are similar to our proposed model for GM assessment that includes farmers as active 
participants and collaborators in the research process, versus other models such as farmers 
conducting corporate sponsored research that are strictly defined by contract agreements. 
 
1. Specific considerations related to informed consent 
One prime ethical criterion for including human participants in investigative research is 
that these individuals make the autonomous decision to participate, i.e., that they are capable of 
providing informed consent to the proposed investigation.(39, para. 13, 22) According to international 
guidelines, such as those in the Declaration of Helsinki,(39) several characteristics and factors of 
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the proposed experimentation must be made clear to the potential participant in order to enable 
informed consent. For one, the relevant hypothesis of the research needs to be stated. Secondly, 
depending on the hypothesis of the research, the participant should stand to benefit (even if only 
indirectly) from the potential results of the research endeavour. Lastly, any predictable risks 
pertaining to the investigation must be made clear and these risks should not outweigh the 
potential benefits (e.g., to the individual, their group or society). These standards were developed 
with attention to biomedical research, thus it is important to examine the particularities or 
differences if these standards are placed in the context of farmer participation in research aiming 
to assess GM crops. 
 
 Information concerning the hypothesis, risks, and benefits for farmer assessments of GM 
crops will indeed be particular. This stems from the rather unique nature of the research to be 
performed. In much of biomedical research, the research participant is a patient subjected to 
specific diagnostics or experimental interventions (e.g., drugs or other medical treatments) – they 
may be more or less actively involved in the study, but they are rarely active in conducting the 
research itself. In other words, not withstanding the current preference in the research ethics 
literature for the more empowering language of participation, patients through their bodies are 
subjected to or are the subject of research; more participatory research nonetheless occurs, 
particular in the context of studies involving rare diseases and the development of some 
biotechnological therapeutics. By contrast, in the study of GM-crops, farmers might be thought 
in some cases to be both the subject of research (alongside the GM-crop) and one of the principle 
researchers.  
 
Agricultural assessment research seeks to determine the utility, safety, etc. of a crop, for 
farmers as participants (e.g., its risks and benefits), and this necessitates that they agree to plant 
the crop in their fields and then document the benefits and risks associated with this product 
during the crop lifecycle. In a sense, then, agricultural technology assessment research involves a 
participant (farmer = patient) testing an intervention (GM crop = medical treatment) in their field 
(farm = patient’s body), and also study the effectiveness and obvious/non-obvious benefits of the 
crop (farmer = researcher or just patient reporting?). Unlike biomedical research, in which 
patients rarely benefit directly (e.g., they may be part of a randomized control trial, be on a 
placebo arm) farmers more often stand to benefit directly from participation (e.g., they are 
usually paid to participate; discussed in the following section) and at the same time may also 
incur substantial economic or environmental risks (e.g., crop failure, development of herbicide 
tolerant weeds). Given these particularities, how then should farmers be informed in order to be 
able to freely consent to participate in GM crop assessment research?  
 
For one, as with biomedical research, it is often technically impractical to provide 
farmers with detailed descriptions of hypothesis, risk, and benefit due to the nature of the 
research being proposed; this information has to be synthesised and made accessible to non-
scientists. In terms of the hypothesis, GM crop developers can provide limited predictions on the 
obvious benefits to be expected from the future cultivation of these crops. However, farmer’s 
assessments might also identify ‘non-obvious’ benefits and risks associated with the technology. 
In all, detailed predictable benefits accruing from farmer participation in assessment initiatives 
are unknown because benefits are one of the key factors to be identified by research participants; 
and the same situation exists for risks. Ill defined risks and benefits related to GM crop 
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assessment raise questions of whether sufficient information can actually be provided to enable 
farmers to clearly consent to participate in such research. Specific ethical attention will need to 
be given to exactly how informed farmers are during recruitment, to ensure fully autonomous 
participation in GM crop assessments. 
 
 When conducting investigative research involving human beings, researchers ought to 
evaluate the informed consent from a wider perspective that includes the ideologies of the 
community in which the research participant is a member. Brody and colleagues, for example, 
note that the informed consent of an individual does not necessarily reflect the collective 
interests or consent of the community where the research is planned to be conducted.(40) When 
evaluating the ethical status of research initiatives, it is essential to consider whether the research 
could expose the community to collective risks.(40) These notions of potential conflict between 
individual and community consent (and interests) require particular vigilance with farmer 
assessments of GM crops.  
 
 The cultivation of GM crops carries potential collective risks to farming communities, 
especially with regards to the ‘co-existence’ of GM and non-GM crops.(41) Discussions 
pertaining to the co-existence of these crops highlight the difficulties that can be encountered 
when agricultural systems must prevent the contamination of non-GM produce by GM crops. In 
order to prevent the intermixing or cross-contamination of GM and non-GM species, agricultural 
systems typically need to develop separate infrastructure for each class of product. This is of 
particular importance in regions where organic farming is practiced.(41) Certified organic produce 
regulations may set strict limits on the permitted presence of GM crops in the organic harvest as 
a criterion for acceptability for the organic food market. If an organic harvest is identified to 
contain evident contamination by GM crops, the harvest will be excluded, an obvious significant 
risk for organic farming communities. Additionally, many of these communities are either 
disinterested or unable to develop the separate infrastructure needed to prevent possible 
contamination. Thus, many organic farming communities collectively agree not to cultivate GM 
crops and even lobby against the introduction of GM crops in neighbouring farms. Thus, despite 
the informed consent of an individual farmer to participate in GM crop assessment initiatives, 
performing such research in organic farming regions could arguably be considered unethical 
because of the substantial collective risk it may pose for the broader agricultural community. 
 
2. Complexities with compensation 
Another issue requiring close scrutiny is how to structure compensation schemes for 
farmers that participate in GM crop research. As already mentioned, in most biomedical research 
(and in human subjects research in the social sciences), it is rare that participants are paid to be 
involved because of the ethical concern that payment would constitute undue influence or 
inducement and thus negate the autonomous choice to participate.(42)‡ To perform such research, 
farmers will need to devote a portion of their agricultural land to experimental cultivation. Since 
it is proposed that farmers intervene in the assessment of these crops prior to their official 
                                                
‡ An exception to this rule against payment is the involvement of healthy participants in Phase 1 clinical trials of 
pharmaceutical drugs, where the goal is to test toxicity and not benefit. In this case, the rationale for payment is that 
these healthy participants are subject to often substantial risk, with no possibility of direct benefits. In contrast, 
patients who are enrolled in Phase 2, 3 or 4 of clinical trials are not paid for their involvement, because there is 
arguably at least the possibility that they can benefit directly (or indirectly, as a member of a patient/disease group).  
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commercialization, the produce from the cultivation of experimental GM crops will need to be 
disposed of and will not be marketed for consumption. Therefore, farmers will need to be 
compensated for any lost production that may accrue from participating in GM crop research. 
They will also need to be compensated for the time and resources they devote towards assessing 
novel GM crops. However, decisions on how to compensate farmers may be more complicated 
than initially predicted. 
 
First, the crops typically cultivated by a farmer may raise problems of injustice. Consider 
the hypothetical situation of a farmer who has the capabilities to cultivate an expensive cash-crop 
that has a high market value (e.g., coffee) and a neighbouring farmer who cultivates a low 
market value staple crop (e.g., potatoes). If both farmers sacrifice an equal proportion of land for 
GM crop assessments, the farmer cultivating the cash-crop will have lost more potential profit 
than will the farmer cultivating the staple crop. Therefore, it might be thought that one farmer 
should receive more compensation for participating in research. But would that be fair? Both 
farmers perform equivalent research activities, so monetary compensation for this activity ought 
to be equivalent. As a comparison, one would not expect to provide more compensation to 
individuals with high salaries, versus individuals with minimum wage jobs, who sacrifice work 
hours to participate in clinical drug trials.§  
 
One method to avoid this injustice is to compensate all farmers with equally generous 
amounts of compensation. However, this method raises the possibility of undue inducement, 
mentioned above.(43) Large compensation factors can provide incentive for people to participate 
in research they would otherwise avoid. In the previously described hypothetical situation, the 
possibility for undue inducement is more likely with the staple-crop farmer relative to the cash-
crop farmer; or between the large scale and small scale farmer. In summary, differences in the 
crops cultivated by farmers (or their scale of farming operation) prior to participation in GM crop 
assessments can complicate decisions on how to distribute compensation ethically. 
 
Second, unique complexities related to compensation can arise from the fact that farmers 
assessing GM crops in their fields will be, as discussed in the previous section on informed 
consent, participating in this research as both a human participant and as a researcher. With the 
proposition that farmers are to identify and document potential problems and benefits with the 
cultivation of experimental GM crops, they occupy a position as an active researcher. This role 
has a vastly different set of responsibilities and tasks to that of daily farming practice. Farmers 
participating in GM crop assessments thus arguably acquire an additional job title – that of 
researcher – and thus ought to be appropriately remunerated during their involvement in the 
assessment process. This then also raises concerns about conflict of interest (similar to those for 
clinician-researchers(44)), as farmers might have a not insignificant financial interest in seeing 
their assessment produce positive results. Thus, the inclusion of farmers in assessment 
procedures requires specific debate about what should constitute appropriate compensation for 
                                                
§ For a discussion of different models of compensation for participants in research, see Dickert, N. and Grady, C., 
What's the Price of a Research Subject? Approaches to Payment for Research Participation, New England Journal 
of Medicine, 1999, 341:198-203; Pentz, R. D., Spreading It Around: Money for Researchers and Research 
Participants, The Mount Sinai Journal of Medicine, 2004, 71 (4):  266-270 
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the cultivation of experimental GM crops, with regards to recompense for the labour involved, 
lost opportunity costs and risks undertaken. 
 
3. Inclusion and exclusion of farmer populations 
Another key factor for conducting ethical research is that the experimental population be 
determined on the principle of inclusion, in order to ensure a just sharing of the benefits and 
burdens of research.(40) In other words, the composition of research participants should not 
favour a particular social group, with the concomitant exclusion of other members of the 
population. While the principle of inclusion appears rather straightforward, marginalized 
individuals and members of vulnerable communities are often still excluded from research, “for 
their benefit” or protection, because their abilities to autonomously consent to participate in 
research are compromised or unattainable.(45) Notable examples of exclusion in medical research 
have included the exclusion of women, children, the elderly or members of visible minority 
groups. While members of these groups have been historically subject to unethical experiments 
and thus are due special protection, exclusion from “risky” research entails that they cannot 
benefit from the results of research, e.g., in terms of access to medications or availability of 
information that may be specific to their particular needs or social circumstance.(46, 47)  
 
Given this background, how does the principle of inclusion and the potential problem of 
exclusion relate to farmers? To begin with, the heterogeneity of farmers requires clarification. 
Farming populations can differ by factors such as geographical location, farming practices (e.g., 
organic or conventional cultivation), and the degree of agricultural industrialization (e.g., 
subsistence farming versus large-scale industrial farming). In terms of geographical location, 
efforts ought to be made to ensure that isolated farming communities (whether in developed or 
developing countries) are not excluded from research opportunities. To expand, isolated 
communities can have fewer resources, technological capacities, necessary infrastructure, and 
visibility to GM crop developers. All these factors contribute to the marginalization of these 
farming communities. Though marginalized, the need for better farming practices in these 
communities should not be viewed as less important than those of more fortunate farming 
communities. It will be impossible for locally relevant GM crops to be developed if the 
communities in which they are to be used are not involved; there are obviously important 
differences between the types of crops to be grown in North America and Europe, and in Latin 
America or Asia. Therefore, vigilance is needed to ensure that different regions as well as 
isolated farming communities have equal opportunities to participate in the assessment of 
experimental GM crops. One notable example to address this issue may be the significant 
expansion of GM crop research in developing countries – particularly in Africa and Asia – that 
specifically focuses on locally relevant crops.  
 
In terms of farming practices, organic farmers would likely be excluded from GM crop 
assessments due to the unwanted possibility for contamination of their organic produce.(41) 
However, this exclusion may be ethically justified since organic farmers would likely make the 
autonomous decision to avoid the presence of GM crops near their organic cultivators, and thus, 
voluntarily not participate in these research opportunities. Yet, the voluntary exclusion of organic 
farmers may still create problems of injustice. This relates back to the discussion of 
compensation of farmers for GM crop assessments. It might be unjust to automatically exclude 
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organic farmers from participating in research to assess emerging GM technologies and receive 
monetary compensation for this activity. 
 
Another concern with regards to just inclusion in research is the degree of agricultural 
industrialization. Efforts should be made to ensure that research assessment of experimental GM 
crops includes small-scale and subsistence farmers as well as large-scale industrial farmers. 
Inclusion of farmers from both small and large-scale operations will identify whether one class 
will stand to receive greater benefit from the future adoption of these GM crops (e.g., the social 
exclusion of subsistence farmers in Brazil associated with that country’s introduction of GM 
soy(34)). Of related concern is the extent to which particular farmer groups may constitute 
vulnerable populations, and thus as has been common in biomedical research,(46, 47) be excluded 
from participating in research because they are illiterate and/or socio-economically deprived and 
thus have reduced autonomous decision making capabilities.(34) Given the likely vulnerable 
status of subsistence farmers, it is particularly important to consider whether they would ever be 
able to provide informed consent to participate in assessments of GM crops. Further, since 
farmers may occupy the role of both research participant and researcher, the illiterate status of 
many subsistence farmers will likely make this group incapable of performing detailed 
technology assessments. It might nonetheless be possible to build in protective measures to 
support this vulnerable group and enable participation in research (e.g., as is done for children or 
incompetent adults in biomedical research), but this will require considerable and detailed ethical 
reflection. 
 
III. CONCLUSION 
 The global agriculture sector has witnessed countless technological advances over the 
past century. Technological progress has transformed farming into a high-technology industry 
and is largely credited with keeping agricultural production in-step with the growing global 
population needs, even though it has not solved the underlying factors related to global hunger. 
Current commercialized GM crops have been observed to provide benefits in the form of better 
pest and weed management and higher production yields; the hope is that these crops can 
provide benefits beyond that of farming practices, to also include social, health and 
environmental benefits. However, the introduction of GM crops into farming systems also 
carriers certain risks, namely that these crops can favour industrial farming practices that further 
marginalize small-scale subsistence or organic farmers. It is thus important that appropriate 
technology assessment procedures be implemented to maximise the benefits of this emerging 
agriculture technology and minimize its risks.  
 
 In this article, we have argued that existing methods to assess GM crops do not promote 
the strategic development and equitable distribution of promising innovations. Government 
regulatory oversight of this technology focuses too exclusively on risk assessments and provides 
little information on associated potential benefits. One method to promote the strategic 
development of GM crops – in line with moves towards broader public participation in policy 
making – is the inclusion of farmers in the assessment and development processes, prior to 
commercialization. Early assessments of experimental GM crops by farmers can identify issues 
pertaining to whether both small and large-scale farmers stand to benefit from the technology. 
Farmer assessments can provide policy makers with the information needed to enact policies that 
promote the development and efficient and equitable introduction of GM crops. But empowering 
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farmers through their participation in the technology assessment process also raises important 
ethical concerns, particularly with regards to the ethical participation in the research process.  
 
Drawing on concepts developed in the field of research ethics, we show that it is 
important to attend to both the similarities with biomedical research (e.g., the need to obtain 
informed consent, protect research participants, and evaluate the balance of harms and benefits 
of research) but also to the differences that arise in the context of agricultural research. In 
particular, it is important to note that farmers may occupy the dual roles of research participant 
and researcher in technology assessment initiatives. This issue is important because it has an 
impact on free and informed consent (what information is sufficient, in what contexts?), and the 
determination of reasonable and fair compensation for participation (should farmers be 
compensated like patients or healthy volunteers in clinical research, or as researchers?), it 
highlights the potential for significant conflicts of interest, and it raises concerns about the 
equitable inclusion of vulnerable groups (e.g., small-scale subsistence farmers, organic farmers) 
in the research process. Attention to these concerns, we believe, can help clarify and better 
structure the ethical responsibilities of the various stakeholders (policy makers, farmers, 
researchers) involved in the assessment and strategic development of new agricultural 
technologies. 
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